Ensysce Biosciences (ENSC) Cash from Operations (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Cash from Operations of 1866179.0 for Q3 2025, down 82.9% year-over-year from 10914643.44 in Q3 2024, and up 31.06% quarter-over-quarter from 2706868.0 in Q2 2025.
Ensysce Biosciences (ENSC) Cash from Operations (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Cash from Operations for 8 consecutive years, with 1866179.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Operations fell 82.9% year-over-year to 1866179.0; the TTM figure through Sep 2025 stood at 7044549.0 (up 17.52% YoY), while the FY2024 annual figure was 7502700.0, up 30.4% from the prior year.
- Cash from Operations advanced to 1866179.0 in Q3 2025 per ENSC's latest filing, from 2706868.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 132312.0 in Q2 2021 and bottomed at 6714311.0 in Q3 2022.
- Historically, Cash from Operations has averaged 2668039.84 across 5 years, with a median of 2706868.0 in 2025.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 3256.08% — and 2023, when it soared 66.3%.
- Ensysce Biosciences' Cash from Operations stood at 3767813.0 in 2021, then gained by 12.53% to 3295620.0 in 2022, then surged by 45.33% to 1801875.0 in 2023, then soared by 57.59% to 764090.0 in 2024, then sank by 144.24% to 1866179.0 in 2025.
- Business Quant data shows ENSC's Cash from Operations at 1866179.0 in Q3 2025, 2706868.0 in Q2 2025, and 1707412.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.87 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Dec 31, 2024 | -764,090.00 |
| Dec 31, 2024 | -764,090.00 |
| Sep 30, 2024 | -1.02 Mn |
| Sep 30, 2024 | -1.02 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -3.41 Mn |
| Mar 31, 2024 | -3.41 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Sep 30, 2023 | -2.26 Mn |
| Sep 30, 2023 | -2.26 Mn |
| Jun 30, 2023 | -3.11 Mn |
| Jun 30, 2023 | -3.11 Mn |